Mucopolysaccharidosis Type II (Hunter Syndrome)
An X-linked inherited enzyme deficiency, occurring almost exclusively in males, that causes progressive accumulation of complex sugars affecting the skeleton, heart, airway, and in the severe form, the central nervous system.
- Enzyme Replacement Therapy
- CNS-Directed Therapy Access
- Multidisciplinary Specialist Coordination
- Estimated Incidence
- ~1 in 100,000–170,000 male births
- Inheritance Pattern
- X-linked Recessive (IDS gene)
- Typical Onset
- Early childhood (2–4 years)
- Therapy Access
- Idursulfase ERT (IV and intrathecal)
Condition Overview
Mucopolysaccharidosis type II (MPS II), known as Hunter syndrome, is a rare X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase. This deficiency leads to progressive accumulation of glycosaminoglycans (GAGs) in tissues throughout the body, affecting the skeleton, joints, heart valves, airway, liver, spleen, and in the severe form, the brain.
Because the IDS gene is located on the X chromosome, Hunter syndrome occurs almost exclusively in males, while female carriers are typically unaffected or have mild symptoms. The disease spans a spectrum from a severe, neuronopathic form with progressive cognitive decline to an attenuated form where intelligence remains largely preserved.
Early recognition allows families to begin enzyme replacement therapy and coordinate multidisciplinary care before significant irreversible organ damage accumulates.
Types and Subtypes
MPS II is classified primarily by the presence or absence of central nervous system involvement.
Symptoms and Signs
Symptoms typically become noticeable between ages 2 and 4, with somatic features often appearing before any neurological signs in the severe form.
Causes and Risk Factors
MPS II results from mutations in the IDS gene on the X chromosome, which encodes iduronate-2-sulfatase, an enzyme required to break down specific glycosaminoglycans. Reduced or absent enzyme activity allows these molecules to accumulate progressively in cells.
Diagnosis and Investigations
Diagnosis relies on a combination of clinical findings, biochemical testing, and genetic confirmation.
Disease Phenotype and Severity Stratification
MPS II does not use a tumor-staging framework. Disease is stratified by neuronopathic status, which most strongly predicts long-term trajectory and guides treatment planning.
Standard Treatment Options
Treatment centers on enzyme replacement therapy to reduce GAG accumulation, combined with coordinated supportive management across affected organ systems.
Advanced & Emerging Therapies
Research efforts in Hunter syndrome are particularly focused on reaching the central nervous system, where standard intravenous enzyme replacement has limited effect.
Enzyme Replacement Therapy
Idursulfase (recombinant iduronate-2-sulfatase)
Intravenous enzyme replacement reduces GAG accumulation in peripheral tissues and improves somatic symptoms such as joint mobility and organ size.
Precision Medicine
Intrathecal idursulfase
Delivered directly into the cerebrospinal fluid in some centers to address neurological manifestations of severe disease not reached by intravenous enzyme replacement.
Gene Therapy
Investigational gene therapy approaches
Gene-addition strategies aiming to provide durable enzyme production, including approaches designed to cross the blood-brain barrier, are in early-to-mid stage clinical trials.
Cellular Therapy
Hematopoietic stem cell transplant
Used selectively in some severe cases, though evidence for CNS benefit in MPS II is less established than in MPS I.
Biomarkers & Precision Diagnostics
Biochemical and genetic markers guide diagnosis, phenotype classification, and treatment monitoring in MPS II.
When a Second Opinion May Be Important
Given the complexity of Hunter syndrome management and the evolving treatment landscape, a specialist second opinion can be valuable at several points in the care journey.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in MPS II depends heavily on whether the severe (neuronopathic) or attenuated form is present, and on how early enzyme replacement therapy and supportive care begin.
Supportive Care and Living With MPS II
Comprehensive supportive care helps manage day-to-day function and quality of life for individuals with Hunter syndrome.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by Hunter syndrome access specialist review of medical reports, coordinate second opinions with metabolic disease specialists, and explore access to enzyme replacement therapy and emerging CNS-directed and gene therapy trials.
Get a free case reviewFrequently Asked Questions
MPS II, or Hunter syndrome, is a rare X-linked disorder caused by deficiency of the enzyme iduronate-2-sulfatase, leading to progressive accumulation of complex sugars in tissues throughout the body, primarily in males.
The IDS gene is located on the X chromosome. Males have only one X chromosome, so a single mutated copy causes disease, while females usually have a second normal copy that compensates.
Severe (neuronopathic) Hunter syndrome involves progressive cognitive decline, while attenuated (non-neuronopathic) disease primarily affects the body's organs and joints with intelligence largely preserved.
Diagnosis combines urine glycosaminoglycan testing, enzyme activity assay for iduronate-2-sulfatase, and confirmatory genetic testing of the IDS gene.
There is no cure, but enzyme replacement therapy with idursulfase can meaningfully reduce somatic disease burden, and CNS-directed approaches are being studied for neurological involvement.
Idursulfase is a recombinant form of iduronate-2-sulfatase given intravenously, and in some centers intrathecally, to reduce glycosaminoglycan buildup.
Female carriers are usually unaffected or have very mild symptoms, though rare cases of symptomatic carriers have been reported.
Yes. It follows an X-linked recessive inheritance pattern, with mothers who carry a mutated IDS gene having a 50% chance of passing it to each son.
Care typically involves metabolic genetics, cardiology, ENT, orthopedics, neurology, and physical therapy working together.
Yes. CancerFax can help coordinate medical report review, connect families with metabolic disease specialists for a second opinion, and explore access to enzyme replacement therapy and investigational CNS-directed or gene therapy trials, including cross-border coordination where appropriate.
Get Specialist Guidance for Your Diagnosis
Connect with metabolic and genetic disease specialists, coordinate a second opinion, and explore therapy access options.